RVNC’s post-offering cash should be ~$300M (on a pro forma basis), after accounting for the $30M due from Fosun Pharmaceuticals (#msg-145245703), approximately ~$35M cash burn since 9/30/18, and proceeds of the new offering (assuming exercise of the underwiter’s option).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”